The pathway of public celebration followed by private concern and then public repudiation damages the industry's credibility and ability to achieve positive outcomes.
It is never too late for a considered response - caution
September 13, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Syntara receives FDA guidance for amsulostat in myelofibrosis treatment
August 11, 2025 - - Australian Biotech -
Noxopharm advances HERACLES trial for novel autoimmune disease drug
August 11, 2025 - - Australian Biotech -
Could the realities of AI quickly date or even swamp the HTA Review outcomes?
August 11, 2025 - - Latest News -
We asked ChatGPT to produce a podcast script explaining the pros and cons of the HTA Review
August 10, 2025 - - Latest News -
PYC Therapeutics accelerates clinical progress of PYC-003 in PKD trial
August 10, 2025 - - Australian Biotech -
Neuren expands NNZ-2591 pipeline to include SYNGAP1-related disorder
August 10, 2025 - - Australian Biotech -
AI has to be seen as a generational opportunity to get medicines to patients faster
August 10, 2025 - - Latest News